SEZARY SYNDROME
Clinical trials for SEZARY SYNDROME explained in plain language.
Never miss a new study
Get alerted when new SEZARY SYNDROME trials appear
Sign up with your email to follow new studies for SEZARY SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells get a navigation system to hunt down lymphoma
Disease control OngoingThis early-phase study tests a new treatment for people with certain types of lymphoma that have not responded to standard therapy or have returned. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack cancer cells, plus a…
Matched conditions: SEZARY SYNDROME
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:27 UTC
-
New pill takes on rare skin cancer in early trial
Disease control OngoingThis early-phase study tests a new drug called tulmimetostat (DZR123) in 24 adults with advanced mycosis fungoides or Sézary syndrome—rare types of skin lymphoma—who have already tried at least one other treatment. The main goals are to check the drug's safety and find the best d…
Matched conditions: SEZARY SYNDROME
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 26, 2026 08:18 UTC
-
Experimental combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a drug called durvalumab, given alone or with lenalidomide, in people with T-cell lymphoma that returned or didn't respond to prior treatments. The goal is to find the best dose and see how well the combination works. About 38 adults with certain types of T-cell …
Matched conditions: SEZARY SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Cancer-killing virus plus immune booster shows promise for rare skin tumors
Disease control OngoingThis study tests a two-step treatment for people with rare skin cancers or certain lymphomas that haven't responded to standard care. First, patients receive a virus-based therapy (talimogene laherparepvec) that infects and kills tumor cells. Then, they also get an immunotherapy …
Matched conditions: SEZARY SYNDROME
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Promising combo targets rare skin cancer
Disease control OngoingThis study tests whether combining two drugs, pembrolizumab and gemcitabine, can shrink tumors in people with advanced mycosis fungoides or Sézary syndrome—rare types of skin lymphoma. The trial enrolled 14 adults who had already tried at least one other treatment. Researchers ar…
Matched conditions: SEZARY SYNDROME
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Engineered donor cells take aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests a new type of CAR T-cell therapy made from donor cells (WU-CART-007) for people with CD7-positive blood cancers, including acute myeloid leukemia and T-cell lymphoma that have not responded to standard treatments. The therapy is designed to target and…
Matched conditions: SEZARY SYNDROME
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 19, 2026 11:47 UTC